{"id":"W4402514945","doi":"10.1038/s41591-024-03261-7","title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Eisai; Jazz Pharmaceuticals; Helsinn; Chugai Pharmaceutical; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006544591,0.0005307394,0.001172477,0.000461959,0.00007294646,0.00002832735,0.0001260008,0.0002575603,0.001421073],"category_scores_gemma":[0.000195441,0.0002748143,0.0001349264,0.001290357,0.0002646541,0.0001549428,0.00002773722,0.001299513,0.0000110793],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004929989,"about_ca_system_score_gemma":0.0007569002,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000622287,"about_ca_topic_score_gemma":0.001959341,"domain_scores_codex":[0.9970938,0.0001876251,0.0005211364,0.0008284277,0.000811312,0.000557721],"domain_scores_gemma":[0.9985876,0.0003751213,0.0001056923,0.0004184717,0.0001485494,0.0003645798],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.373913,0.003725791,0.0007261355,0.001029258,0.002836894,0.01654948,0.004013293,0.00002404004,0.003009088,0.0007982633,0.01479388,0.5785809],"study_design_scores_gemma":[0.7918764,0.04738769,0.004747567,0.01750932,0.006359969,0.007537172,0.005052903,0.001219453,0.003895198,0.0002426753,0.1128244,0.00134716],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8667395,0.03523666,0.001117048,0.08647384,0.001657148,0.005911041,0.001245941,0.0003768787,0.001241979],"genre_scores_gemma":[0.9900013,0.000338842,0.001584992,0.00432577,0.001229735,0.0004390901,0.0003619948,0.00009830116,0.001619938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5772337,"threshold_uncertainty_score":0.9999704,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01226947485604996,"score_gpt":0.3775639384676909,"score_spread":0.365294463611641,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}